Skip to main content

Advertisement

Table 1 Demographics and case characteristics of EIB and TB-AOI cases - Alberta, 2004–14

From: Program-wide review and follow-up of erythema Induratum of Bazin and tuberculosis-associated ocular inflammation management in a TB low-incidence setting: need for improved treatment candidate selection, therapy standardization, and care collaboration

  EIB (n = 22) TB-AOI (n = 20)
Female gender – no. (%) 17 (77) 11 (55)
Age – years
 Median (IQR) 43 (8.3) 38 (17.8)
Country of origin – no. (%)
 TB-HBC* 18 (82) 14 (70)
History of latent TB− no. (%) 4 (18) 4 (20)
Duration of Symptoms – months (years) n = 19 n = 15
 Median 24 (2) 9 (0.8)
 IQR 30 (2.5) 13 (1.1)
Diagnostics
 TST n = 16 n = 16
  Range - induration (mm) 10–30 12–40
  Median (IQR) 18 (7) 17.5 (7.8)
 IGRA n = 13 (7 had TST) n = 15 (11 had TST)
  Positive result – no. (%) 12 (92) 13 (87)
 Chest X-ray n = 22 n = 20
  TB changes§ – no. (%) 4 (18) 1 (5)
Tissue Biopsy Pathology# n = 17  
Granulomatous inflammation 15 (88) No samples obtained for
Necrobiosis 9 (53) pathology
Panniculitis 10 (59)  
Vasculitis 8 (47)  
  1. *TB-HBC = TB High Burden Country as per WHO classification [40]
  2. TB history = reported prior exposure, documented TST conversion (positive after a prior negative), or prior LTBI therapy
  3. TST = tuberculin skin test, IGRA = interferon-gamma release assay (QuantiFERON-TB Gold In-Tube Test)
  4. §TB changes (no.) = upper lobe calcification (2), multilobar ‘infiltrate’ (1), nodule (1), hilar lymphadenopathy (1)
  5. Pathology sums to > 100% as multiple patterns present in some specimens, No AFB or organisms seen in any samples